TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scinai Immunotherapeutics ( (SCNI) ) has shared an announcement.
Scinai Immunotherapeutics Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for December 22, 2025, in Tel Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, amendments to the company’s Articles of Association, and various grants of options and shares to directors and officers as part of cost-cutting measures. These decisions are aimed at recognizing contributions and incentivizing leadership, while also implementing strategic financial adjustments. The meeting will also ratify the appointment of Ziv Haft as the company’s auditors for 2025, ensuring continued financial oversight.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on the development of immunotherapeutic products. The company is based in Jerusalem, Israel, and is involved in advancing treatments that leverage the body’s immune system to combat diseases.
Average Trading Volume: 139,555
Technical Sentiment Signal: Sell
Current Market Cap: $934K
Learn more about SCNI stock on TipRanks’ Stock Analysis page.